ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Millennium Pharmaceuticals has announced an agreement to acquire AnorMED for $515 million, a price representing a 40% premium over the hostile bid for AnorMED made by Genzyme in August (C&EN, Sept. 4, page 23). Millennium's target in the acquisition is the Canadian firm's hematology-oncology therapy Mozobil, a small-molecule chemokine antagonist currently in Phase III clinical trials. Mozobil has been shown to mobilize bone marrow stem cells in myeloma and lymphoma patients undergoing transplantation. According to Millennium CEO Deborah Dunsire, it would complement her firm's Velcade, a myeloma drug codeveloped with Johnson & Johnson.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter